Recombinant Human uPAR Protein (His Tag)(Active) | PKSH031353

(No reviews yet) Write a Review
SKU:
575-PKSH031353
€794.00
Frequently bought together:

Description

Recombinant Human uPAR Protein (His Tag)(Active) | PKSH031353 | Gentaur US, UK & Europe Disrtribition

Synonyms: Urokinase Plasminogen Activator Surface Receptor; U-PAR; uPAR; Monocyte activation antigen;Mo3; CD87; PLAUR; MO3; UPAR

Active Protein: Active protein

Activity: A DNA sequence encoding the human UPAR isoform 1 (Q03405-1) (Met 1-Arg 303) without the pro peptide was expressed, with a carboxy-terminal polyhistidine tag.

Protein Construction: A DNA sequence encoding the human UPAR isoform 1 (Q03405-1) (Met 1-Arg 303) without the pro peptide was expressed, with a carboxy-terminal polyhistidine tag.

Fusion Tag: C-His

Species: Human

Expressed Host: HEK293 Cells

Shipping: This product is provided as lyophilized powder which is shipped with ice packs.

Purity: > 98 % as determined by reducing SDS-PAGE.

Endotoxin: < 1.0 EU per µg of the protein as determined by the LAL method.

Stability and Storage: Generally, lyophilized proteins are stable for up to 12 months when stored at -20 to -80℃. Reconstituted protein solution can be stored at 4-8℃ for 2-7 days. Aliquots of reconstituted samples are stable at < -20℃ for 3 months.

Molecular Mass: 32.8 kDa

Formulation: Lyophilized from sterile PBS, pH 7.4

Reconstitution: Please refer to the printed manual for detailed information.

Background: Urokinase plasminogen activator (uPA) and/or its receptor (uPAR) are essential for metastasis, and overexpression of these molecules is strongly correlated with poor prognosis in a variety of malignant tumours. uPAR and uPA levels in both resected tumor tissue and plasma are of independent prognostic significance for patient survival in several types of human cancer. This system has classically been thought to drive tumor progression by mediating directed extracellular proteolysis on the surface of migrating or invading cells, and intervening with this proteolysis by targeting uPAR has been proposed to represent a novel approach for inhibiting tumor progression. uPAR, also known as PLAUR or CD87, has been implicated in the growth, metastasis, and angiogenesis of several solid and hemotologic malignancies. uPAR is a highly glycosylated, 55-60kDa integral membrane protein linked to the plasma membrane by a glycosylphosphatidylinositol (GPI) anchor. It is part of a cell surface system that also consists of the serine protease uPA and several specific inhibitors (plasminogen activator inhibitors 1 and 2). Additionally, the analysis of CD87 (urokinase-type plasminogen activator receptor - uPAR) expression has a potential role in the diagnostic or prognostic work-up of several hematological malignancies, particularly acute leukemia and multiple myeloma.

Research Area: N/A

View AllClose